Cypromed

Cypromed is a biotechnology company based in Innsbruck, Austria, that specializes in the development of advanced oral delivery systems for peptides and proteins. The company's proprietary technology platform utilizes a combination of specific protease inhibitors and absorption enhancers to overcome the physiological barriers of the gastrointestinal tract. By protecting biologics from enzymatic degradation and improving their permeability, Cypromed enables the systemic administration of drugs that are traditionally limited to injections. The company primarily focuses on metabolic diseases, with lead internal programs targeting the oral delivery of insulin and GLP-1 receptor agonists. Cypromed's mission is to improve patient compliance and therapeutic outcomes by transforming injectable treatments into convenient oral formulations.